SABS
SAB Biotherapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
SAB Biotherapeutics has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
—
SAB Biotherapeutics, Inc.
3.31
−0.04 · −1.34%
post 3.31 0.00%
SentenceThe Emergent Agreements contemplate that we will enter into one or more binding Master Manufacturing Services Agreements, whereby Emergent will provide contract development and manufacturing services to produce our fully-human polyclonal antibody products.
SentenceFor SAB-142, Avance Clinical PTY, Ltd ("Avance"), acts as the contract research organization ("CRO") overseeing our Phase 1 safety study.
SABS 10-Kaccession 0001833214-26-000003
SentenceFortrea will act as the CRO overseeing our Phase 2b efficacy and safety study for SAB-142.
SABS 10-Kaccession 0001833214-26-000003
SentenceWe acquired all the intellectual property rights to Tc Bovine and the production platform from Sanford Applied Biosciences, a wholly owned subsidiary of Sanford Health, to develop targeted hIgG to specific targets and advance clinical development and commercialization.
SABS 10-Kaccession 0001833214-26-000003
SentenceWe had various grants from the US Department of Defense that terminated in 2022.
SABS 10-Kaccession 0001833214-26-000003
Linked news
Expected move
No implied move.